Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors.
• GISTs are typically driven by mutations in KIT or PDGFRA tyrosine kinases.
• Standard chemotherapy and radiation are ineffective against GIST.

Purpose of the Study:

• To review current and emerging therapeutic strategies for imatinib-refractory GIST.
• To explore novel agents and combinations targeting GIST resistance mechanisms.
• To discuss the potential of these novel approaches in first-line and adjuvant settings.

Main Methods:

• Review of current literature on GIST targeted therapy.
• Analysis of biologic data on imatinib resistance mechanisms in GIST.
• Evaluation of novel agents tested as single agents or in combination with imatinib.

Main Results:

• Imatinib therapy revolutionized GIST treatment but resistance is a significant challenge.
• Emerging therapies leverage understanding of resistance mechanisms.
• Novel agents show promise for overcoming imatinib resistance.

Conclusions:

• Targeted therapy, particularly imatinib, has transformed GIST management.
• Development of novel agents is crucial to address imatinib resistance.
• Future GIST treatment regimens will likely involve novel agents alone or in combination with imatinib.